New clinical data confirm that the CFTR modulator combination elexacaftor/tezacaftor/ivacaftor (ETI) delivers measurable clinical benefit in children with cystic fibrosis, extending the therapy’s impact across younger age groups. The findings support broader pediatric adoption and ongoing regulatory and payer discussions about access to highly effective modulators. Investigators reported improvements in lung function and other clinically relevant endpoints consistent with adult datasets, reinforcing ETI’s role as a disease-modifying therapy in CF. Sponsors and clinicians cited the data as validation for early intervention strategies.